The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...

NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

Pfizer ends its collaboration with Sangamo Therapeutics on a haemophilia A gene therapy despite strong Phase III results and ...

Unfortunately, Sangamo recently publicized a shocking setback that Pfizer (PFE) has decided to terminate their partnership for their hemophilia A gene therapy program. This announcement has nearly ...

NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

Sangamo plans to explore all options to commercialize the Hemophilia A asset.